ArticleAnnals of intensive care2025
Association of metformin administration after septic shock with short-term and long-term survival in septic shock patients with diabetes.
Article in Annals of intensive care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association of preadmission metformin use and prognosis in patients with sepsis with diabetes: a systematic review and meta-analysis.Frontiers in endocrinology · 2026 · on this mapPooled it
- Validation of the updated sequential organ failure assessment (SOFA)-2 score in emergency department septic shock.Journal of intensive care · 2026Article
- Immunometabolism, an emerging field in perioperative and critical care medicine: a narrative review.British journal of anaesthesia · 2026Review
- The interplay between type 2 diabetes mellitus and sepsis: a scoping review.International journal of medical sciences · 2026Article
- Mitochondrial dysfunction in sepsis-associated acute kidney injury: mechanisms and therapeutic potential.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundIn addition to glycemic control, the anti-inflammatory effects and protective effect of metformin on sepsis have been reported in animal studies, which may be beneficial for patients with septic shock. Few observational studies have evaluated metformin administration after sepsis or bacteremia; however, these studies did not specifically analyze septic shock or long-term outcomes. Therefore, this study aimed to evaluate the associations between metformin administration after septic shock and the short- and long-term survival in septic shock patients with type 2 diabetes mellitus.
methodThis retrospective observational study used data from a prospectively collected sepsis registry. From October 2016 to June 2022, adult septic shock patients with type 2 diabetes mellitus were included in this study. The variable of interest was metformin administration within 48 h after diagnosis of septic shock. The 90-day mortality and 365-day mortality were evaluated as outcomes. A multivariable Cox proportional hazards model was conducted.
resultsA total of 320 patients were included in the study. Metformin administration within 48 h after diagnosis of septic shock was associated with lower 90-day mortality (13.0% vs. 39.8%, P < 0.001), 365-day mortality (23.3% vs. 48.3%, P = 0.001), and in-hospital mortality (9.3% vs. 28.6%, P = 0.002) than those who did not administer metformin within 48 h. Metformin administration within 48 h was independently associated with decreased 90-day mortality (adjusted hazard ratio [aHR]: 0.371, 95% confidence interval [CI]: 0.153-0.900, P = 0.028) and 365-day mortality (aHR 0.453, 95% CI 0.219-0.937, P = 0.033) after adjusting for potential confounders. Similar results were found for metformin administration within 72 h after septic shock (aHR 0.433, 95% CI 0.235-0.797, P = 0.007 for 90-day mortality and aHR 0.450, 95% CI 0.264-0.767, P = 0.003 for 365-day mortality).
conclusionsIn septic shock patients with type 2 diabetes mellitus, metformin administration within 48 h was associated with lower 90-day and 365-day mortality. While these findings suggest potential benefits of metformin administration after septic shock, further large, multicenter studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.